This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4SC-207

4SC AG

Drug Names(s): 4SC-207

Description: 4SC-207 is a novel, orally available cell-cycle blocker (CCB) for the treatment of tumours resistant to chemotherapy. This anti-mitotic compound inhibits the division of actively proliferating tumour cells. In preclinical testing, apoptosis was observed in dividing cancer cells only, rather than in non-proliferating cells.

4SC-207 News

Scrip Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Scrip Swift And Nimble – Alembic Laps Up US Valsartan Windfall In Q2

Pink Sheet Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup

Scrip Chugai Explores New Tech In Strategic Push For Innovation

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug